Nakamura R, Yamada T, Tokuda S, Morimoto K, et al. Triple combination therapy comprising osimertinib, an AXL inhibitor, and an FGFR inhibitor improves the efficacy of EGFR-mutated non-small cell lung cancer. Cancer Lett 2024;598:217124.
PMID: 39059573